Literature DB >> 17477360

Distinct roles of individual Smads in skin carcinogenesis.

Sophia Bornstein1, Kristina Hoot, Gang-Wen Han, Shi-Long Lu, Xiao-Jing Wang.   

Abstract

Transforming growth factor beta (TGFbeta) signaling has both tumor suppression and promotion roles. Smads are transcription factors that primarily mediate intracellular signaling for the TGFbeta superfamily. Loss of Smad2 and Smad4, but not Smad3 is common in human cancers. Given the complex nature of TGFbeta signaling, dissection of the distinct role of each Smad in mediating the multiple functions of TGFbeta signaling is warranted. To further analyze Smad deregulation during carcinogenesis, Smad2, Smad3, Smad4, and Smad7 were genetically modified in murine epidermis, and each alteration resulted in distinct skin phenotypes. Based on data from human cancer samples and from experimental models, Smad2 and Smad4 mainly function as tumor suppressors in skin carcinogenesis in vivo, whereas Smad3 and Smad7 may have dual roles in cancer. This review intends to summarize recent advances in the elucidation of the roles of Smad2, Smad3, Smad4, and Smad7 in skin carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17477360     DOI: 10.1002/mc.20336

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  11 in total

1.  Genome-wide screening of indicator genes for assessing the potential carcinogenic risk of Nanjing city drinking water.

Authors:  Rui Zhang; Shupei Cheng; Aimin Li; Jie Sun; Yan Zhang; Xuxiang Zhang
Journal:  Ecotoxicology       Date:  2011-03-22       Impact factor: 2.823

Review 2.  Role of Smad7 in inflammatory bowel diseases.

Authors:  Giovanni Monteleone; Roberta Caruso; Francesco Pallone
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

3.  Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications.

Authors:  Erika L Abel; Joe M Angel; Kaoru Kiguchi; John DiGiovanni
Journal:  Nat Protoc       Date:  2009-08-27       Impact factor: 13.491

4.  Bone morphogenetic protein antagonist noggin promotes skin tumorigenesis via stimulation of the Wnt and Shh signaling pathways.

Authors:  Andrey A Sharov; Andrei N Mardaryev; Tatyana Y Sharova; Marina Grachtchouk; Ruzanna Atoyan; H Randolph Byers; John T Seykora; Paul Overbeek; Andrzej Dlugosz; Vladimir A Botchkarev
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

5.  Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation.

Authors:  Sophia Bornstein; Ruth White; Stephen Malkoski; Masako Oka; Gangwen Han; Timothy Cleaver; Douglas Reh; Peter Andersen; Neil Gross; Susan Olson; Chuxia Deng; Shi-Long Lu; Xiao-Jing Wang
Journal:  J Clin Invest       Date:  2009-10-19       Impact factor: 14.808

6.  Signal transduction molecules as targets for cancer prevention.

Authors:  Ann M Bode; Zigang Dong
Journal:  Sci Signal       Date:  2009-02-24       Impact factor: 8.192

7.  Elevating CLIC4 in Multiple Cell Types Reveals a TGF- Dependent Induction of a Dominant Negative Smad7 Splice Variant.

Authors:  Anjali Shukla; Yihan Yang; Sara Madanikia; Yan Ho; Mangmang Li; Vanesa Sanchez; Christophe Cataisson; Jing Huang; Stuart H Yuspa
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

8.  Smad3-dependent CCN2 mediates fibronectin expression in human skin dermal fibroblasts.

Authors:  Trupta Purohit; Zhaoping Qin; Chunji Quan; Zhenhua Lin; Taihao Quan
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

9.  Cutaneous HPV8 and MmuPV1 E6 Proteins Target the NOTCH and TGF-β Tumor Suppressors to Inhibit Differentiation and Sustain Keratinocyte Proliferation.

Authors:  Jordan M Meyers; Aayushi Uberoi; Miranda Grace; Paul F Lambert; Karl Munger
Journal:  PLoS Pathog       Date:  2017-01-20       Impact factor: 6.823

10.  Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.

Authors:  Juan F Santibanez
Journal:  ISRN Dermatol       Date:  2013-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.